Guide

Pharmaceutical GMP readiness in China

China's drug framework is set by the Drug Administration Law (2019 revision) and the Provisions for Drug Registration (2020). The National Medical Products Administration (NMPA) regulates drugs; the Center for Food and Drug Inspection (CFDI / NIFDC) conducts GMP inspections. China-GMP (2010, with subsequent revised annexes including the 2020 Annex on Data Integrity) is technically aligned with EudraLex Vol 4 / WHO TRS but is enforced independently — China is an ICH member since 2017 but is NOT a PIC/S member. Marketing requires an MAH established in China. This guide covers the China-specific layer.

Start free trial Free trial, no credit card, onboard in days, not months.

Regulator and legal basis

NMPA sits under the State Administration for Market Regulation. CDE handles registration review; CFDI conducts GMP inspections; provincial MPAs license domestic sites. Statutory base: Drug Administration Law 2019; Provisions for Drug Registration 2020; 2010 GMP plus revised annexes (sterile, biologicals, APIs, TCM, IMPs, data integrity).

MAH system and imported drugs

The MAH (Marketing Authorization Holder) system, introduced nationally in 2019, separates the licence holder from the manufacturer. Foreign manufacturers cannot hold the MAH directly — they appoint a designated Chinese legal entity as the MAH agent. Imported drugs require an Imported Drug Licence (IDL) and on-site inspection of the foreign manufacturing site by CFDI.

Drug code, language, and labelling

China operates a national drug electronic supervision code (药品电子监管码) — a unique identifier on saleable packs reported through the NMPA hub for high-risk classes (vaccines fully; broader categories being phased in). All labelling and IFU must be in simplified Chinese; submissions are in Chinese with English supporting allowed.

Inspection style and common findings

CFDI inspections are intensive and often unannounced. Outcomes feed into licence retention and may trigger product recall. Common findings: data integrity (the 2020 annex is enforced strictly), deviation/CAPA, sterile/Annex 1 equivalent contamination control, and supplier qualification of imported APIs. China is not in PIC/S — EU/US inspection reports are referenced but not formally relied upon.

A 90–180 day China readiness path

Days 0–30: appoint MAH agent; identify IDL scope and product registrations. Days 31–90: align documentation to 2010 GMP and the data-integrity annex; prepare simplified Chinese labelling. Days 91–180: pre-inspection readiness with bilingual records; host CFDI inspection. Plan 6–18 months for full registration timelines.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

ALCOA+

The nine-letter mnemonic regulators use to grade your data integrity — and what every Part 11 audit really tests.

EU Annex 11

European equivalent of 21 CFR Part 11 — rules for computerised systems in GMP.

EU GMP Annex 1 Sterile

EU GMP Annex 1 (revision effective 25 August 2023, with full lyophilisation-section compliance from 25 August 2024) is the world's most influential sterile-manufacturing standard — adopted by EU, MHRA

ICH Q10

The international model for a Pharmaceutical Quality System covering the entire product lifecycle from development to discontinuation.

Data integrity

ALCOA+ — data must be Attributable, Legible, Contemporaneous, Original, Accurate (+ Complete, Consistent, Enduring, Available).

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Industries this hits hardest

Frequently asked

Is China a PIC/S member?

Not as of 2026. China is an ICH member (since 2017) and has substantially converged on ICH guidelines, but NMPA inspections do not rely on PIC/S partners' GMP certificates — CFDI will inspect foreign sites for imported drugs.

Do we need a Chinese MAH or can we hold our own MA?

Foreign manufacturers cannot hold the MAH directly. A Chinese legal entity must hold the MAH role, with documented agreements covering quality oversight, pharmacovigilance, and recall responsibility.

How strict is China on data integrity?

Very. The 2020 Annex on Data Integrity codified ALCOA+ expectations; CFDI inspectors actively examine audit trails, instrument software user management, and contemporaneous records. Hybrid (paper + electronic) systems are a frequent finding area.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →